Ulrike Schatz

1.1k total citations
39 papers, 362 citations indexed

About

Ulrike Schatz is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ulrike Schatz has authored 39 papers receiving a total of 362 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Surgery, 13 papers in Cardiology and Cardiovascular Medicine and 13 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ulrike Schatz's work include Lipoproteins and Cardiovascular Health (29 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Ulrike Schatz is often cited by papers focused on Lipoproteins and Cardiovascular Health (29 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Ulrike Schatz collaborates with scholars based in Germany, United Kingdom and United States. Ulrike Schatz's co-authors include Ulrich Julius, Sabine Fischer, Stefan R. Bornstein, Bernd Hohenstein, Sergey Tselmin, Gabriele Müller, Gabriele Siegert, Andreas L. Birkenfeld, Jens Passauer and Heinz Reichmann and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Heart Journal and International Journal of Obesity.

In The Last Decade

Ulrike Schatz

37 papers receiving 352 citations

Peers

Countries citing papers authored by Ulrike Schatz

Since Specialization

Citations

This map shows the geographic impact of Ulrike Schatz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrike Schatz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrike Schatz more than expected).

Fields of papers citing papers by Ulrike Schatz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrike Schatz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrike Schatz. The network helps show where Ulrike Schatz may publish in the future.

Co-authorship network of co-authors of Ulrike Schatz

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrike Schatz. A scholar is included among the top collaborators of Ulrike Schatz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrike Schatz. Ulrike Schatz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment strategies and LDL cholesterol target attainment in patients with statin intolerance: Insights from the multicentre statin intolerance registry 2025 ·American Journal of Preventive Cardiology ·(unknown), Julius L. Katzmann, (unknown), (unknown), (unknown), Ulrike Schatz, Andrea Baessler, Wolfgang Köenig, Stephan H. Schirmer, (unknown), Oliver Weingärtner, Ursula Kassner, Ulrich Laufs	1
2	Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia 2025 ·American Heart Journal ·Ulf Landmesser, Ulrich Laufs, Ulrike Schatz, Ephraim B. Winzer, Bernd Nowak, (unknown), (unknown), (unknown), Lawrence Lubyayi, (unknown), (unknown), Christian Hentschke, (unknown), Maciej Banach	1
3	Lipid-lowering treatment of patients with statin intolerance – Interim analysis of an observational, prospective, multicenter registry 2023 ·Atherosclerosis ·(unknown), (unknown), Ulrike Schatz, Oliver Weingärtner, Ursula Kassner, Ioanna Gouni‐Berthold, Ulrich Laufs	0
4	State of the Art: Lipoproteinapherese 2023 ·DMW - Deutsche Medizinische Wochenschrift ·Ulrike Schatz, Volker Schettler, Ulrich Julius	4
5	Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study 2022 ·SHILAP Revista de lepidopterología ·Ioanna Gouni‐Berthold, Frank Schäper, Ulrike Schatz, (unknown), Uwe Fraass, (unknown), Kausik K. Ray	9
6	Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor 2021 ·Global Cardiology Science and Practice ·(unknown), Ulrike Schatz, Stefan R. Bornstein, Mahmoud Barbir	2
7	Short- and long-term effects of lipoprotein apheresis on plasma hormones in patients with therapy-resistant dyslipidemia 2019 ·Atherosclerosis Supplements ·(unknown), Ulrich Julius, Sergey Tselmin, Ulrike Schatz, Stefan R. Bornstein, J. Graessler	1
8	Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels 2019 ·Atherosclerosis Supplements ·Ulrich Julius, Sergey Tselmin, Ulrike Schatz, Sabine Fischer, Andreas L. Birkenfeld, Stefan R. Bornstein	16
9	Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis 2019 ·Atherosclerosis Supplements ·Sergey Tselmin, Ulrich Julius, (unknown), Stefan R. Bornstein, Ulrike Schatz	4
10	Extracorporeal apheresis therapy for Alzheimer disease—targeting lipids, stress, and inflammation 2019 ·Molecular Psychiatry ·Stefan R. Bornstein, (unknown), Peter Rosenthal, Sergey Tselmin, Ulrich Julius, Ulrike Schatz, Bernhard O. Boehm, Sandrine Thuret, Gerd Kempermann, Heinz Reichmann, George P. Chrousos, Julio Licínio, Ma‐Li Wong, Andrew V. Schally, Richard Straube	21
11	Lipoprotein(a)—an interdisciplinary challenge 2019 ·PubMed ·Ulrich Julius, (unknown), Ulrike Schatz, Sabine Fischer, Stefan R. Bornstein	2
12	Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic 2019 ·Atherosclerosis Supplements ·Ulrike Schatz, Sabine Fischer, Gabriele Müller, Sergey Tselmin, Andreas L. Birkenfeld, Ulrich Julius, Winfried März, Stefan R. Bornstein	10
13	The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgery 2018 ·International Journal of Obesity ·Christian von Loeffelholz, Lidia Castagneto‐Gissey, Tina Schumann, Christine Henke, (unknown), Joachim Struck, Andreas Bergmann, M Hanefeld, Ulrike Schatz, Stefan R. Bornstein, Giovanni Casella, Geltrude Mingrone, Andreas L. Birkenfeld	14
14	Lipoprotein apheresis influences monocyte subpopulations 2017 ·Atherosclerosis Supplements ·Stefanie Jellinghaus, (unknown), Ulrike Schatz, (unknown), Karim Ibrahim, Christian Pfluecke, Antje Schauer, Stefan R. Bornstein, Bernd Hohenstein, R. H. Strasser, Ulrich Julius, David M. Poitz	2
15	Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia 2017 ·Atherosclerosis Supplements ·(unknown), Gabriele Müller, Ulrike Schatz, Ulrich Julius, Stefan R. Bornstein, Bernd Hohenstein	7
16	Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol 2017 ·Diabetes Therapy ·Christoph Schindler, Andreas L. Birkenfeld, M Hanefeld, Ulrike Schatz, (unknown), (unknown), Diethelm Tschöpe, Matthias Blüher, Christoph Hasslacher, Stefan R. Bornstein	8
17	Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden 2015 ·Atherosclerosis Supplements ·(unknown), Ulrike Schatz, Bernd Hohenstein, Ulrich Julius	15
18	The Effects of Pretreatment versus De Novo Treatment with Selective Serotonin Reuptake Inhibitors on Short-term Outcome after Acute Ischemic Stroke 2015 ·Journal of Stroke and Cerebrovascular Diseases ·Timo Siepmann, Jessica Kepplinger, Charlotte Zerna, Ulrike Schatz, Ana Isabel Penzlin, Lars‐Peder Pallesen, Ben Min-Woo Illigens, Kerstin Weidner, Heinz Reichmann, Volker Puetz, Ulf Bodechtel, Kristian Barlinn	16
19	Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations 2013 ·Atherosclerosis Supplements ·Ulrike Schatz, Borros Arneth, Gabriele Siegert, (unknown), Sven Fischer, Ulrich Julius, Stefan R. Bornstein	6
20	Why an Apheresis Center Should Offer More Than One Lipoprotein Apheresis Method 2012 ·Therapeutic Apheresis and Dialysis ·Ulrich Julius, Sabine Fischer, Ulrike Schatz, Jens Passauer, Stefan R. Bornstein	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact